WYE-125132 (also known as WYE-132) is a potent and selective inhibitor of mTOR (mammalian target of rapamycin), a key protein kinase involved in regulating cell growth, proliferation, and survival. It is widely used in research settings to study the mTOR signaling pathway, particularly in the context of cancer and metabolic diseases. Its primary application lies in oncology research, where it helps scientists understand how mTOR inhibition affects tumor cell growth and survival. WYE-132 has shown activity against various cancer cell lines by blocking both mTORC1 and mTORC2 complexes, which may lead to more complete suppression of the pathway compared to earlier inhibitors like rapamycin. It is also used to investigate cellular processes such as autophagy, protein synthesis, and insulin signaling. Due to its ability to cross the blood-brain barrier in preclinical models, it has been explored in neurological disorders where mTOR signaling is dysregulated, such as epilepsy and neurodegenerative conditions. In addition, WYE-132 serves as a tool compound in drug development, helping to validate mTOR as a therapeutic target and guiding the design of new clinical candidates. While not used clinically, its pharmacological profile supports the development of similar agents for potential therapeutic use.